The global sarcoma drugs market size is expected to be valued at USD 2534.5 million by 2030, as per a new report by Grand View Research, Inc., progressing at a CAGR of 8.9% from 2023 to 2030. The growth of the market is largely driven by factors such as new product launches, increasing adoption of novel therapeutics, and growing target population.

Sarcomas account for less than 1.0% of all adult cancers. Though sarcomas represent a heterogeneous group of over 50 different histological subtypes, the two major subtypes are soft tissue sarcomas (STS) and bone sarcoma. Approximately, 12,000 patients in the U.S. and 28,000 patients in Europe are diagnosed with STS every year.

For over 40 years, the mainstay of localized sarcoma treatment included surgical resection followed by neoadjuvant or adjuvant radiation or chemotherapy. However, even after complete surgical resection, about 50.0% of patients with intermediate or high grade sarcoma develop metastatic disease. The introduction of targeted therapy has revolutionized the treatment paradigm for sarcoma. Targeted therapies and pipeline breakthroughs will continue to play a pivotal role in the growth of the market throughout the forecast period.

Sarcoma Drugs Market Report Highlights

• EU5 will remain the second largest market with more than 20% share by 2022. The growth of the segment can be attributed to the rising incidence of STS, uptake of targeted therapies, and increasing R&D activities
• Eli Lilly’s Lartuvo has displaced standard doxorubicin therapy as front-line STS treatment and is anticipated to maintain its prominence in the market over the forecast period
• Strong unmet needs within the market present a key opportunity to develop breakthrough first-in-class therapies. Out of 45 drugs in the pipeline for sarcoma, seven are in Phase III, 22 in Phase II, two in Phase I/II trials, and the remaining in Phase I and Pre-clinical trials
• The potential role for use of immuno-oncology agents in sarcomas is currently under evaluation in Phase I/II clinical trials
• Drugs with novel targets in early-phase development include Novartis’s Afinitor (mTOR inhibitor), Tesaro’s Zejula (PARP inhibitor), Amgen’s Imlygic (gene therapy), and Pfizer’s Crizotinib (ALK and MET tyrosine kinases inhibitor)

Sarcoma Drugs Market Segmentation

Grand View Research has segmented the global sarcoma drugs market based on treatment type, distribution channel and region:

Sarcoma Drugs Treatment Type Outlook (Revenue, USD Million, 2018 - 2030)

• Chemotherapy
• Targeted Therapy & Others

Sarcoma Drugs Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

• Hospital pharmacy
• Retail pharmacy
• Online pharmacy

Sarcoma Drugs Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America
  • US
  • Canada
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Sweden
  • Norway
  • Denmark
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East & Africa
  • Saudi Arabia
  • South Africa
  • UAE
  • Kuwait

Key Players in Sarcoma Drugs Market

• Pfizer Inc.
• Novartis AG
• Eli Lilly and Company
• Bayer AG
• Eisai Co., Ltd
• Johnson & Johnson
• Merck & Co., Inc.
• Daiichi Sankyo Company, Limited

Order a free sample PDF of the Sarcoma Drugs Market Intelligence Study, published by Grand View Research.